Last reviewed · How we verify

Standard of care antifungal prophylaxis

Fernanda P Silveira, MD, MS · Phase 3 active Small molecule

Standard of care antifungal prophylaxis is a Antifungal Small molecule drug developed by Fernanda P Silveira, MD, MS. It is currently in Phase 3 development for Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation. Also known as: Fluconazole, voriconazole, or no prophylaxis.

This drug works by inhibiting the growth of fungi.

This drug works by inhibiting the growth of fungi. Used for Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation.

At a glance

Generic nameStandard of care antifungal prophylaxis
Also known asFluconazole, voriconazole, or no prophylaxis
SponsorFernanda P Silveira, MD, MS
Drug classAntifungal
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Standard of care antifungal prophylaxis drugs typically work by inhibiting the growth of fungi through various mechanisms, such as interfering with cell wall synthesis or inhibiting the production of essential nutrients. This can help prevent the spread of fungal infections in patients who are at high risk.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of care antifungal prophylaxis

What is Standard of care antifungal prophylaxis?

Standard of care antifungal prophylaxis is a Antifungal drug developed by Fernanda P Silveira, MD, MS, indicated for Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation.

How does Standard of care antifungal prophylaxis work?

This drug works by inhibiting the growth of fungi.

What is Standard of care antifungal prophylaxis used for?

Standard of care antifungal prophylaxis is indicated for Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation.

Who makes Standard of care antifungal prophylaxis?

Standard of care antifungal prophylaxis is developed by Fernanda P Silveira, MD, MS (see full Fernanda P Silveira, MD, MS pipeline at /company/fernanda-p-silveira-md-ms).

Is Standard of care antifungal prophylaxis also known as anything else?

Standard of care antifungal prophylaxis is also known as Fluconazole, voriconazole, or no prophylaxis.

What drug class is Standard of care antifungal prophylaxis in?

Standard of care antifungal prophylaxis belongs to the Antifungal class. See all Antifungal drugs at /class/antifungal.

What development phase is Standard of care antifungal prophylaxis in?

Standard of care antifungal prophylaxis is in Phase 3.

What are the side effects of Standard of care antifungal prophylaxis?

Common side effects of Standard of care antifungal prophylaxis include Nausea, Diarrhea, Vomiting, Abdominal pain, Headache.

Related